Is dabigatran safe in CKD?

It's usable down to CrCl 15 with the 75 mg BID dose, but it's the NOAC with the steepest renal clearance — so in stage G4-G5, most clinicians prefer apixaban. Above CrCl 50, dabigatran's outcomes are excellent and it has the only fully specific reversal antidote.

Direct oral anticoagulant (Direct thrombin inhibitor)

Dabigatran (Pradaxa) and Kidneys and Kidneys

Brand names: Pradaxa • Drug class: Direct oral anticoagulant (Direct thrombin inhibitor)

Dabigatran is the most kidney-dependent of the NOACs (~80% renally cleared). Dosing is tightly tied to CrCl: 150 mg BID above 50, 75 mg BID at 15-30 (US label), and it's avoided below CrCl 15 and on dialysis.

How it affects the kidneys

Because dabigatran is mostly excreted by the kidneys, levels rise sharply as GFR falls — bleeding risk climbs. That's why it has the strictest renal rules of the NOACs, and why apixaban is usually preferred in advanced CKD. It does have an antidote (idarucizumab).

Evidence at a glance

75 mg BID for CrCl 15-30 (US label); avoid <15 and in dialysis

FDA Pradaxa prescribing information, 2024

Higher bleeding vs apixaban at reduced renal function in real-world CKD analyses

Real-world NOAC comparisons in CKD, 2022

Idarucizumab (Praxbind) available as reversal agent

RE-VERSE AD trial (Pollack CV et al., NEJM 2017), 2017

Renal dosing guidance

CrCl >30: 150 mg BID (some labels allow 110 mg BID in Europe for age ≥80). CrCl 15-30: 75 mg BID (US). CrCl <15 or dialysis: avoid. In elderly with additional bleeding risk factors, the lower dose is often chosen.

Check your kidney function